Advertisement

Der Gynäkologe

, Volume 50, Issue 11, pp 860–866 | Cite as

Gestationsbedingte Trophoblasttumoren

Leitthema

Zusammenfassung

Die gestationsbedingten Trophoblasttumoren schließen eine Gruppe von seltenen schwangerschaftsbedingten Tumoren ein, die aus den prämalignen Läsionen der Blasenmole und der Partialmole, wie aus den bösartigen Tumoren der invasiven Mole, des Chorionkarzinoms und des sehr seltenen Plazentabetttumors bestehen. Mit verbesserter Diagnose und Therapie übersteigt heute das Gesamtüberleben die Rate von 98 %, während die meisten Frauen vor 60 Jahren an den malignen Formen gestorben wären. Dieser Erfolg lässt sich durch die Entwicklung effektiver Behandlungen, die Verwendung von menschlichem Choriongonadotropin (hCG) als Biomarker und die Zentralisierung der onkologischen Versorgung erklären. Therapieansätze für gestationsbedingte Trophoblasttumoren werden diskutiert und Follow-up-Maßnahmen angesprochen.

Schlüsselwörter

Gestationsbedingte Trophoblasterkrankungen Invasive hydatidiforme Mole Choriongonadotropin Chorionkarzinom Biomarker 

Gestational trophoblastic tumors

Abstract

Gestational trophoblastic disease includes a group of rare pregnancy-related tumors, consisting of premalignant lesions of complete and partial hydatidiform moles and the malignant tumors of invasive moles, choriocarcinoma and the rare placental site trophoblastic tumor. With improved diagnosis and therapy the overall survival rate now exceeds 98% whereas 60 years ago most women would have died from the malignant forms of the disease. This success can be explained by the development of effective forms of treatment, the use of human chorionic gonadotropin as a biomarker and centralization of oncological care. Therapy approaches for gestational trophoblastic disease are addressed and appropriate follow-up measures are discussed.

Keywords

Gestational trophoblastic disease Invasive hydatidiform mole Chorionic gonadotropin Choriocarcinoma Biomarkers 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

C. Mundhenke gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Seckl MJ, Sebire NJ, Berkowitz RS (2010) Gestational trophoblastic disease. Lancet 376:717–729CrossRefPubMedGoogle Scholar
  2. 2.
    Mangili G, Lorusso D, Brown J, Pfisterer J, Massuger L et al (2014) Trophoblastic disease review for diagnosis and management. Int J Gynecol Cancer 24:S109–S116CrossRefPubMedGoogle Scholar
  3. 3.
    Berkowitz RS, Goldstein DP (2009) Clinical practice. Molar pregnancy. N Engl J Med 360:1639–1645CrossRefPubMedGoogle Scholar
  4. 4.
    Savage PM, Sita-Lumsden A, Dickson S et al (2013) The relationship of maternal age to molar pregnancy incidence, risks for chemotherapy and subsequent pregnancy outcome. J Obstet Gynaecol 33:406–411CrossRefPubMedGoogle Scholar
  5. 5.
    Fu J, Fang F, Xie L et al (2012) Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.CD007289.pub2 PubMedGoogle Scholar
  6. 6.
    Deicas RE, Miller DS, Rademaker AW et al (1991) The role of contraception in the development of postmolar gestational trophoblastic tumor. Obstet Gynecol 78:221–226PubMedGoogle Scholar
  7. 7.
    Schmid P, Nagai Y, Agarwal R et al (2009) Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. Lancet 374:48–55CrossRefPubMedGoogle Scholar
  8. 8.
    Mangili H, Larusso D, Brown J et al (2014) Trophoblastic disease review for diagnosis and management: a joint report from the international society for the study of trophoblastic disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer Intergroup. Int J Gynecol Cancer 24(9):S109–S116CrossRefPubMedGoogle Scholar
  9. 9.
    Mangili G, Garavaglia E, Cavoretto P et al (2008) Clinical presentation of hydatidiform mole in northern Italy: has it changed in the last 20 years? Am J Obstet Gynecol 198:302.e1–302.e4CrossRefGoogle Scholar
  10. 10.
    Gestational and Non-gestational Trophoblastic Disease. Guideline of DGGG, OEGGG and SGGG (S2k Level, AWMF Registry No. 032/049, December 2015)Google Scholar
  11. 11.
    Horn LC, Einenkel J, Vogel M (2009) Histopathology of gestational trophoblastic disease. An update, Pathologe. 30(4):313–323CrossRefPubMedGoogle Scholar
  12. 12.
    Natalia Buza, Pei Hui, (2014) Immunohistochemistry and other ancillary techniques in the diagnosis of gestational trophoblastic diseases. Seminars in Diagnostic Pathology 31 (3):223-232CrossRefPubMedGoogle Scholar
  13. 13.
    Xia ZF, Song HZ, Tang MY (1980) Risk of malignancy and prognosis using a provisional scoring system in hydatidiform mole. Chin Med J 93:605–612PubMedGoogle Scholar
  14. 14.
    Elias K, Goldstein DP, Berkowitz RS (2010) Complete hydatidiform mole in women older than age 50. J Reprod Med 55:208–212PubMedGoogle Scholar
  15. 15.
    Sebire NJ, Foskett M, Paradinas FJ et al (2002) Outcome of twin pregnancies with complete hydatidiform mole and healthy co-twin. Lancet 359:2165–2166CrossRefPubMedGoogle Scholar
  16. 16.
    Agarwal R, Teoh S, Short D et al (2012) Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study. Lancet 379:130–135CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Ngan HY, Bender H, Benedet JL, Jones H, Montruccoli GC, Pecorelli S (2003) Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet 83(Suppl 1):175–177CrossRefPubMedGoogle Scholar
  18. 18.
    Seckl MJ, Sebire NJ, Fisher RA et al (2013) Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(suppl 6):vi50–vi39CrossRefGoogle Scholar
  19. 19.
    Lurain JR, Schink JC (2012) Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia. J Reprod Med 57:219–224PubMedGoogle Scholar
  20. 20.
    Newlands ES, Mulholland PJ, Holden L et al (2000) Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol 18:854–859CrossRefPubMedGoogle Scholar
  21. 21.
    Alifrangis C, Agarwal R, Short D et al (2013) EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol 31:280–286CrossRefPubMedGoogle Scholar
  22. 22.
    Neubauer NL, Latif N, Kalakota K et al (2012) Brain metastasis in gestational trophoblastic neoplasia: an update. J Reprod Med 57:288–292PubMedGoogle Scholar
  23. 23.
    Yang J, Xiang Y, Wan X et al (2006) The prognosis of gestational trophoblastic neoplasia patient with residual lung tumor after completing treatment. Gynecol Oncol 103:479–482CrossRefPubMedGoogle Scholar
  24. 24.
    Mapelli P, Mangili G, Picchio M et al (2013) Role of 18 F-FDG PET in the management of gestational trophoblastic neoplasia. Eur J Nucl Med Mol Imaging 40:505–513CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH 2017

Authors and Affiliations

  1. 1.FrauenklinikUniversitätsklinikum Schleswig-HolsteinKielDeutschland

Personalised recommendations